Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by EMD Serono

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT
From EMD Serono
Via Business Wire
EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies
From EMD Serono
Via Business Wire
EMD Serono to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025
From EMD Serono
Via Business Wire
EMD Serono Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
From EMD Serono
Via Business Wire
Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor
From EMD Serono
Via Business Wire
EMD Serono Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025
From EMD Serono
Via Business Wire
EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash
From EMD Serono
Via Business Wire
EMD Serono Appoints Miguel Fernández Alcalde to Lead North American Healthcare Business
From EMD Serono
Via Business Wire
Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial
From EMD Serono
Via Business Wire
EMD Serono Unveils New MAVENCLAD® Four-Year Data Highlighting Benefits of Early Treatment and Sustained Efficacy Across Multiple Measures of Disease Activity
From EMD Serono
Via Business Wire
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)
From EMD Serono
Via Business Wire
Merck KGaA, Darmstadt, Germany’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment
From EMD Serono
Via Business Wire
EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
From EMD Serono
Via Business Wire
EMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefits
From EMD Serono
Via Business Wire
Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
From EMD Serono
Via Business Wire
Merck KGaA, Darmstadt, Germany, Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna
From EMD Serono
Via Business Wire
EMD Serono Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District
From EMD Serono
Via Business Wire
EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023
From EMD Serono
Via Business Wire
Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit Up to Five Years in People with RMS
From EMD Serono
Via Business Wire
EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation
From EMD Serono
Via Business Wire
EMD Serono Launches New Collaboration with United Nations-Guided Global Initiative on Ageing to Support Caregivers
From EMD Serono
Via Business Wire
EMD Serono Highlights Commitment to Improving Cancer Outcomes at ASCO 2023
From EMD Serono
Via Business Wire
Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)
From EMD Serono
Via Business Wire
EMD Serono Highlights New Four-Year Efficacy and Safety Data for Investigational BTK Inhibitor, Evobrutinib, in RMS
From EMD Serono
Via Business Wire
New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma
From EMD Serono
Via Business Wire
EMD Serono Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment
From EMD Serono
Via Business Wire
EMD Serono Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care
From EMD Serono
Via Business Wire
Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care
From EMD Serono
Via Business Wire
EMD Serono to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients
From EMD Serono
Via Business Wire
EMD Serono Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways
From EMD Serono
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.